Find out about our advocacy in action regarding the Peter Rabbit movie and our ask of Sony. Plus, read about the latest on the Viaskin Peanut and Milk patches, and watch a video where Dr. Azad speaks about the work on the developmental origins of disease in children.
Advocacy in action: Letter to Sony regarding Peter Rabbit movie
We sent a letter to Sony Pictures Entertainment regarding the portrayal of food allergy in the movie Peter Rabbit. We are calling on Sony to take the lead in driving positive change around food allergy awareness and education in the film industry.
DBV Technologies: Updates on Viaskin patch
There were two releases by DBV Technologies last month:
1. Viaskin Peanut patch: DBV Technologies announced that the U.S. Food and Drug Administration (FDA) agreed that the available efficacy and safety data for Viaskin Peanut supports the submission of a Biologics License Application for treatment of peanut allergy in children 4-11 years of age. This means that this is a step forward in terms of potential approval of Viaskin Peanut. Read the full release.
2. Viaskin Milk patch: DBV Technologies announced positive preliminary results from a Phase II study of the Viaskin Milk patch in patients with milk allergy. These results support Viaskin Milk’s potential as a treatment for patients with milk allergy. The study was designed to determine a safe and effective dose in two age groups: children aged 2-11 and youth aged 12-17. Read the full release.
Watch: Studying chronic diseases in children
Watch a video with AllerGen investigator Dr. Meghan Azad produced by the Human Capital and Economic Opportunity (HCEO) Global Working Group. Dr. Azad speaks about the work on the developmental origins of disease in children, touching on the influence of maternal and infant nutrition, including breastfeeding, and the role of the infant gut microbiome.
Watch the video below. AllerGen is a national research network dedicated to improving the quality of life of people with allergic and related immune diseases.